The relationship between NLRP3 rs10159239 and Vaspin rs2236242 gene variants and obstructive sleep apnea.
Elisa
NLRP3
Obstructive sleep apnea
polymorphism
vaspin
Journal
Upsala journal of medical sciences
ISSN: 2000-1967
Titre abrégé: Ups J Med Sci
Pays: Sweden
ID NLM: 0332203
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
02
2021
revised:
22
04
2021
accepted:
04
05
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
14
1
2022
Statut:
epublish
Résumé
In obstructive sleep apnea (OSA), recurrent upper airway obstruction and apnea/hypopnea episodes result in endothelial dysfunction, which leads to the release of many proinflammatory cytokines and reactive oxygen species (ROS). ROS induces NLRP3, a protein involved in the synthesis of interleukin (IL)-1 and IL-18; vaspin is a serine protease inhibitor that has an important role in suppressing the activation of NLRP3 inflammasome. In this study, we aimed to investigate the effect of NLRP3 rs10159239 (rs9239) and vaspin rs2236242 (rs6242) single nucleotide polymorphisms (SNPs) on OSA development. This study included 220 individuals who underwent polysomnography (118 patients with OSA and 102 healthy controls). NLRP3 rs9239 and vaspin rs6242 mutation frequencies were analyzed. The NLRP3 rs9239 SNP genotype analysis revealed no statistically significant differences between the OSA and control groups. In the vaspin gene analysis, the rs6242 AA genotype was significantly more frequent in the OSA group compared with the control group, while the AT genotype was more frequent in controls ( The vaspin rs6242 SNP AA genotype increased susceptibility to OSA, while the AT genotype appeared to be protective. The lower plasma vaspin levels in OSA compared with the control group and in patients with the AA genotype suggest that vaspin may be a protective biomarker for OSA.
Sections du résumé
BACKGROUND
BACKGROUND
In obstructive sleep apnea (OSA), recurrent upper airway obstruction and apnea/hypopnea episodes result in endothelial dysfunction, which leads to the release of many proinflammatory cytokines and reactive oxygen species (ROS). ROS induces NLRP3, a protein involved in the synthesis of interleukin (IL)-1 and IL-18; vaspin is a serine protease inhibitor that has an important role in suppressing the activation of NLRP3 inflammasome. In this study, we aimed to investigate the effect of NLRP3 rs10159239 (rs9239) and vaspin rs2236242 (rs6242) single nucleotide polymorphisms (SNPs) on OSA development.
METHODS
METHODS
This study included 220 individuals who underwent polysomnography (118 patients with OSA and 102 healthy controls). NLRP3 rs9239 and vaspin rs6242 mutation frequencies were analyzed.
RESULTS
RESULTS
The NLRP3 rs9239 SNP genotype analysis revealed no statistically significant differences between the OSA and control groups. In the vaspin gene analysis, the rs6242 AA genotype was significantly more frequent in the OSA group compared with the control group, while the AT genotype was more frequent in controls (
CONCLUSION
CONCLUSIONS
The vaspin rs6242 SNP AA genotype increased susceptibility to OSA, while the AT genotype appeared to be protective. The lower plasma vaspin levels in OSA compared with the control group and in patients with the AA genotype suggest that vaspin may be a protective biomarker for OSA.
Identifiants
pubmed: 34349888
doi: 10.48101/ujms.v126.7603
pii: 7603
pmc: PMC8276347
doi:
Substances chimiques
NLR Family, Pyrin Domain-Containing 3 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 The Author(s). Published by Upsala Medical Society.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Eur Respir J. 2016 Mar;47(3):910-8
pubmed: 26743485
Sleep Med Rev. 2003 Feb;7(1):35-51
pubmed: 12586529
JAMA. 2003 Oct 8;290(14):1906-14
pubmed: 14532320
Gene. 2017 Aug 30;626:140-148
pubmed: 28479386
J Cell Physiol. 2021 May;236(5):3734-3739
pubmed: 33078402
Chest. 2000 Sep;118(3):580-6
pubmed: 10988175
Eur J Endocrinol. 2011 Jun;164(6):905-10
pubmed: 21471167
Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700
pubmed: 19628778
Sleep Breath. 2019 Jun;23(2):535-542
pubmed: 30284175
Respir Med. 2009 Mar;103(3):386-92
pubmed: 19022640
Lancet. 2002 Jul 20;360(9328):237-45
pubmed: 12133673
Gene. 2020 Jan 30;725:144163
pubmed: 31639433
Cytokine. 2004 Oct 21;28(2):87-91
pubmed: 15381186
Biochem Biophys Res Commun. 2019 Jun 18;514(1):1-8
pubmed: 31014675
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Inflammation. 2018 Aug;41(4):1321-1333
pubmed: 29656319
Sleep Med Rev. 2015 Apr;20:27-45
pubmed: 25155182
Otolaryngol Pol. 2015;69(2):1-8
pubmed: 26224223
Nat Rev Immunol. 2010 Mar;10(3):210-5
pubmed: 20168318
Respiration. 2015;90(2):105-10
pubmed: 26088934
J Cell Physiol. 2019 Feb 20;:
pubmed: 30786009
Biomolecules. 2019 Dec 09;9(12):
pubmed: 31835423
Lung. 2020 Apr;198(2):275-282
pubmed: 32088750
Zhonghua Jie He He Hu Xi Za Zhi. 2006 Aug;29(8):536-40
pubmed: 17074267
J Thorac Dis. 2014 Jun;6(6):720-5
pubmed: 24976995
Curr Protoc Hum Genet. 2008 Apr;Chapter 1:Unit 1.18
pubmed: 18428419
Inflamm Res. 2014 Jan;63(1):33-43
pubmed: 24121974
Endocr Rev. 2006 Dec;27(7):762-78
pubmed: 17056740